FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Core Viewpoint - The FDA has agreed to review Moderna's experimental mRNA flu shot, reversing its earlier decision, which has surprised both Wall Street and the medical community [1][2]. Group 1: FDA Review and Approval Process - The FDA is expected to make a decision on the flu shot by August 5, which is crucial for Moderna's plans to introduce the vaccine for the upcoming influenza season [2]. - Moderna aims for full approval of the flu shot for adults aged 50 to 64 and accelerated approval for those aged 65 and older, which will require a post-marketing study to confirm benefits [5]. - The FDA's acceptance of the modified application follows a "constructive" meeting where Moderna proposed a revised regulatory approach addressing previous criticisms [4][5]. Group 2: Clinical Trial and Regulatory Concerns - The FDA had previously criticized Moderna's choice of comparator in its phase three trial, stating it did not reflect the best standard of care in the U.S. [6]. - Moderna contends that FDA guidelines do not mandate the use of the highest-dose vaccine as a comparator and argues that the agency's prior communications supported their trial design [8]. - The decision to initially refuse the application was influenced by the FDA's top vaccine regulator, who has advocated for stricter vaccine regulations [9][10]. Group 3: Market Reaction and Company Outlook - Following the announcement of the FDA's review, shares of Moderna increased by over 6% [3]. - The successful introduction of the flu vaccine is integral to Moderna's goal of achieving financial break-even by 2028 [2].